Detalhe da pesquisa
1.
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
Ann Oncol
; 35(5): 414-428, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38431043
2.
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.
Gynecol Oncol
; 166(1): 44-49, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35491267
3.
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Ann Oncol
; 32(6): 757-765, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667670
4.
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Gynecol Oncol
; 160(3): 688-695, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33390325
5.
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Ann Oncol
; 31(9): 1148-1159, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569725
6.
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Gynecol Oncol
; 157(3): 585-592, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32247603
7.
Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
Ann Oncol
; 30(5): 721-732, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30887020
8.
Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
Gynecol Oncol
; 155(1): 69-74, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31409486
9.
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Ann Oncol
; 29(5): 1304-1311, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29788155
10.
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Ann Oncol
; 29(4): 917-923, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29401246
11.
Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Gynecol Oncol
; 174: 278-287, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315373
12.
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
Ann Oncol
; 33(10): 989-991, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964823
13.
Homologous recombination deficiency testing in first-line ovarian cancer.
Ann Oncol
; 33(3): 231-233, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35017033
14.
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.
Ann Oncol
; 28(4): 702-710, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28119296
15.
PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials.
Ann Oncol
; 32(8): 1048-1050, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107345
16.
Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
Ann Oncol
; 32(8): 1066-1067, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34090767
17.
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Ann Oncol
; 27(11): 2124-2130, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27793850
18.
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Gynecol Oncol
; 130(2): 377-82, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23632208
19.
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?
Gynecol Oncol
; 125(1): 94-8, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22155415
20.
Malignant melanoma of the vulva: an extension of cutaneous melanoma?
Gynecol Oncol
; 122(3): 612-7, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21570710